ENTITY
Abbisko

Abbisko (2256 HK)

36
Analysis
Health CareChina
Abbisko Cayman Limited is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule oncology therapies. Its pipeline includes core product candidates like ABSK011 (Irpagratinib) for hepatocellular carcinoma and ABSK091 (Fexagratinib) for urothelial and gastric cancers, along with Pimicotinib (ABSK021) for tenosynovial giant cell tumors. The company was founded in 2016 and is headquartered in Shanghai, China.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x